Mark T. J. van Bussel

Author

The Netherlands Cancer Institute ORCID

Also Known As

M.T.J. van Bussel, MARK T.J. VAN BUSSEL, Mark T J van Bussel, Mark T. J. van Bussel, Mark T.J. van Bussel

Publications

466

Citations

H-Index

Concepts

All Affiliations

The Netherlands Cancer Institute Utrecht University Radboud University Nijmegen KU Leuven Oncode Institute

About

Mark T. J. van Bussel is an author at The Netherlands Cancer Institute specializing in medicine, clinical chemistry, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	117
2	Pharmacology	2	2	117
3	Immunology	1	1	75
4	Medical Laboratory Science	1	1	75
5	Pathology	1	1	42

Mark T. J. van Bussel

Publications

417

Citations

H-Index

Page 1

	Year	Citations
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours Mark T. J. van Bussel, Ahmad Awada, Maja J.A. de Jonge, British Journal of Cancer	2020	117
Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid Dick Pluim, Willeke Ros, Mark T. J. van Bussel, Journal of Pharmaceutical and Biomedical Analysis Autoimmune DiseaseMedicineCerebrospinal FluidBioanalysisPharmacology	2018	75
Circulating epithelial tumor cell analysis in CSF in patients with leptomeningeal metastases Mark T. J. van Bussel, Dick Pluim, Bojana Milojkovic Kerklaan, Neurology	2020	63
Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review Mark T. J. van Bussel, Jos H. Beijnen, Dieta Brandsma BMC Cancer	2019	60
A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF<i>V600E</i>-Mutant<i>KRAS</i>Wild-Type Metastatic Colorectal Cancer Josep Tabernero, Eric Van Cutsem, Elena Garralda, The Oncologist	2023	46
Liquid chromatography–tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma Johannes J.M. Rood, Mark T. J. van Bussel, Jan H.M. Schellens, Journal of Chromatography B Therapeutic Drug MonitoringSclerostinMedicineMass SpectrometryBiological Mass Spectrometry	2016	42
Dose selection and tolerability of anticancer agents evaluated by the European Medicines Agency in the period 2015-2020 Marc Maliepaard, W. Carree, Mark T. J. van Bussel ESMO Open	2021	14

Page 1